[go: up one dir, main page]

MX2023009569A - Terapia de combinacion para cancer de prostata. - Google Patents

Terapia de combinacion para cancer de prostata.

Info

Publication number
MX2023009569A
MX2023009569A MX2023009569A MX2023009569A MX2023009569A MX 2023009569 A MX2023009569 A MX 2023009569A MX 2023009569 A MX2023009569 A MX 2023009569A MX 2023009569 A MX2023009569 A MX 2023009569A MX 2023009569 A MX2023009569 A MX 2023009569A
Authority
MX
Mexico
Prior art keywords
prostate cancer
combination therapy
effective amount
therapeutically effective
inhibitor
Prior art date
Application number
MX2023009569A
Other languages
English (en)
Inventor
Margaret K Yu
Linda Anne Snyder
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62067858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2023009569(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2023009569A publication Critical patent/MX2023009569A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Se proporcionan métodos y composiciones para tratar el cáncer de próstata al administrar a un paciente en necesidad de este una cantidad terapéuticamente eficaz de un inhibidor de PARP, p. ej., niraparib; una cantidad terapéuticamente eficaz de un inhibidor de CYP17, p. ej., acetato de abiraterona, y una cantidad terapéuticamente eficaz de un glucocorticoide, p. ej., prednisona.
MX2023009569A 2017-04-13 2019-10-14 Terapia de combinacion para cancer de prostata. MX2023009569A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762485164P 2017-04-13 2017-04-13

Publications (1)

Publication Number Publication Date
MX2023009569A true MX2023009569A (es) 2023-08-22

Family

ID=62067858

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019012296A MX2019012296A (es) 2017-04-13 2018-04-09 Terapia de combinacion para cancer de prostata.
MX2023009569A MX2023009569A (es) 2017-04-13 2019-10-14 Terapia de combinacion para cancer de prostata.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019012296A MX2019012296A (es) 2017-04-13 2018-04-09 Terapia de combinacion para cancer de prostata.

Country Status (33)

Country Link
US (4) US20180296574A1 (es)
EP (3) EP4176878A1 (es)
JP (3) JP7141408B2 (es)
KR (1) KR20190134718A (es)
CN (2) CN110753545A (es)
AU (2) AU2018251594A1 (es)
CA (1) CA3059562A1 (es)
CL (1) CL2019002871A1 (es)
CO (1) CO2019011591A2 (es)
CR (1) CR20190467A (es)
DK (1) DK3609497T3 (es)
DO (1) DOP2019000264A (es)
EA (1) EA201992430A1 (es)
ES (1) ES2931052T3 (es)
HR (1) HRP20221327T1 (es)
HU (1) HUE060460T2 (es)
IL (2) IL320452A (es)
JO (1) JOP20190244A1 (es)
LT (1) LT3609497T (es)
MA (1) MA48728B1 (es)
MD (1) MD3609497T2 (es)
MX (2) MX2019012296A (es)
MY (1) MY209010A (es)
NI (1) NI201900105A (es)
PE (1) PE20200444A1 (es)
PH (1) PH12019502317A1 (es)
PL (1) PL3609497T3 (es)
PT (1) PT3609497T (es)
RS (1) RS63832B1 (es)
SG (1) SG11201909552VA (es)
SM (1) SMT202200467T1 (es)
UA (1) UA129514C2 (es)
WO (1) WO2018191141A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3490560T1 (sl) 2016-07-29 2025-04-30 Janssen Pharmaceutica, N.V. Niraparib za uporabo pri metodi zdravljenja raka prostate
WO2020139339A1 (en) * 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
CN116785301A (zh) 2019-09-26 2023-09-22 湖南慧泽生物医药科技有限公司 含醋酸阿比特龙的药物组合物及其制备方法和应用
JP7442328B2 (ja) * 2020-02-03 2024-03-04 株式会社三共 遊技機
CN113546037B (zh) * 2020-04-20 2024-12-27 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
AU2021267146A1 (en) * 2020-05-08 2023-01-19 Janssen Pharmaceutica Nv Treatments of prostate cancer with combinations of abiraterone acetate and niraparib
CN114306236B (zh) * 2021-12-15 2022-10-21 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
WO2023109758A1 (en) 2021-12-15 2023-06-22 Hunan Huize Biopharma S&T Co., Ltd Abiraterone acetate-containing composition and application thereof
KR20240170958A (ko) * 2022-04-07 2024-12-05 아스트라제네카 아베 암 치료를 위한 병용 요법
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法
CN121443291A (zh) * 2023-08-02 2026-01-30 詹森药业有限公司 尼拉帕尼和阿比特龙组合用于治疗转移性去势抵抗性前列腺癌

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
KR20180003636A (ko) * 2006-08-25 2018-01-09 코우가 바이오테크놀로지, 인크. 암을 치료하기 위한 방법 및 조성물
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
WO2009087381A1 (en) 2008-01-08 2009-07-16 Merck Sharp & Dohme Ltd Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2014089324A1 (en) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use

Also Published As

Publication number Publication date
MA48728B1 (fr) 2022-10-31
DOP2019000264A (es) 2020-07-15
UA129514C2 (uk) 2025-05-21
CN110753545A (zh) 2020-02-04
PL3609497T3 (pl) 2023-01-23
EP4176878A1 (en) 2023-05-10
BR112019021466A2 (pt) 2020-05-12
IL320452A (en) 2025-06-01
CO2019011591A2 (es) 2020-02-28
MD3609497T2 (ro) 2023-03-31
HRP20221327T1 (hr) 2023-03-17
MY209010A (en) 2025-06-16
PH12019502317A1 (en) 2020-07-06
EP3609497A1 (en) 2020-02-19
NI201900105A (es) 2020-03-11
JP2022141881A (ja) 2022-09-29
CL2019002871A1 (es) 2019-12-27
DK3609497T3 (da) 2022-10-31
US20240398837A1 (en) 2024-12-05
JP2024023344A (ja) 2024-02-21
IL269879B2 (en) 2025-10-01
IL269879B1 (en) 2025-06-01
WO2018191141A1 (en) 2018-10-18
EA201992430A1 (ru) 2020-02-28
AU2018251594A1 (en) 2019-10-24
PT3609497T (pt) 2023-01-23
EP3609497B1 (en) 2022-10-12
SG11201909552VA (en) 2019-11-28
ES2931052T3 (es) 2022-12-23
CA3059562A1 (en) 2018-10-18
JP2020516646A (ja) 2020-06-11
CR20190467A (es) 2020-03-09
PE20200444A1 (es) 2020-02-28
MA48728A (fr) 2020-04-08
KR20190134718A (ko) 2019-12-04
AU2024202346A1 (en) 2024-05-02
LT3609497T (lt) 2022-12-12
CN119235874A (zh) 2025-01-03
AU2024202346B2 (en) 2026-01-22
SMT202200467T1 (it) 2023-01-13
JP7407880B2 (ja) 2024-01-04
EP4176879A1 (en) 2023-05-10
US20240245710A1 (en) 2024-07-25
JOP20190244A1 (ar) 2019-10-13
MX2019012296A (es) 2019-11-28
JP7141408B2 (ja) 2022-09-22
IL269879A (es) 2019-11-28
US20180296574A1 (en) 2018-10-18
HUE060460T2 (hu) 2023-03-28
RS63832B1 (sr) 2023-01-31
US20220175801A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
MX2023009569A (es) Terapia de combinacion para cancer de prostata.
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
CL2009001011A1 (es) Uso del compuesto 21-metoxi-17a-acetoxi-11ß-(4-n,n­-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona (cdb-4124) para tratar el cancer de mama; y uso de la combinacion de cdb-4124 con un inhibidor de aromatasa.
MX385762B (es) Métodos para el control transcripcional objetivo en regiones del super mejorador.
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2020001727A (es) Terapia de combinacion.
MX2019013862A (es) Terapia de combinacion.
MX2017011237A (es) Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides.
CO2021000923A2 (es) Formulaciones de un inhibidor de axl/mer
MX2019003694A (es) Metodos para tratar cancer del tracto biliar.
PH12020550151A1 (en) Methods of treating prostate cancer
MX2018015916A (es) Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.
BR112022022590A2 (pt) Formulações farmacêuticas de acetato de abiraterona e niraparibe
MX2024012392A (es) Terapia combinada para el tratamiento del cancer
MX2024012369A (es) Terapia combinada para el tratamiento del cancer
MX2020013805A (es) Derivados de piridopirimidinona para uso como inhibidores de axl.
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
MX2024009923A (es) Metodos para tratar el cancer de prostata.